{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:28:47Z","timestamp":1740126527261,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"am","delay-in-days":290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.semarthrit.2024.152434","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:17:52Z","timestamp":1710523072000},"page":"152434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Unique characteristics of anti-MDA-5 associated dermatomyositis in Southern California with a large Hispanic population"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1459-7376","authenticated-orcid":false,"given":"Eaman","family":"Alhassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belina Y.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Crew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanna","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semarthrit.2024.152434_bib0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152434_bib0002","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152434_bib0003","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0004","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152434_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.semarthrit.2024.152434_bib0007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/1346-8138.14092","article-title":"Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis","volume":"45","author":"Li","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152434_bib0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fmed.2020.00363","article-title":"Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: a Series of 474 Patients","volume":"7","author":"Li","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152434_bib0010","article-title":"Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: a Systematic Review and Meta-Analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152434_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2177\/jsci.36.71","article-title":"Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia","volume":"36","author":"Nakashima","year":"2013","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152434_bib0012","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152434_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152434_bib0014","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152434_bib0015","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3899\/jrheum.160024","article-title":"Gottron papules and gottron sign with ulceration: a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis","volume":"43","author":"Cao","year":"2016","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152434_bib0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north american patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152434_bib0017","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152434_bib0018","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","article-title":"Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis","volume":"35","author":"Xu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152434_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152434_bib0021","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152434_bib0022","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152434_bib0023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0024","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12969-021-00574-6","article-title":"Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies","volume":"19","author":"Perron","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152434_bib0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152434_bib0026","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152434_bib0027","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Ll Wilkinson","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152434_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","article-title":"Anti-MDA5 Antibody Spectrum in Western World","volume":"20","author":"Moghadam-Kia","year":"2018","journal-title":"Curr Rheumatol Rep"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:47:21Z","timestamp":1718416041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722400074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"alternative-id":["S004901722400074X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152434","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unique characteristics of anti-MDA-5 associated dermatomyositis in Southern California with a large Hispanic population","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152434"}}